glp-1 makers Insulin, to face 340B price-fixing class action suit FIRST GLP-1 PILL: The FDA
Description
Customer service is amazing and I do so well on their program
GLP-1 exerts anti-inflammatory effects by suppressing the NF-B signaling pathway, which leads to a decrease in the production of pro-inflammatory cytokines like TNF- and IL-6, thereby mitigating liver inflammation and fibrosis
At the same time, the equity questions are just as important as the efficacy curves: Who will actually have access to orforglipron once it is approved
However, the exact mechanism of SCFA-induced gut peptide release is controversial, as SCFAs may activate EECs via basolateral sensing mechanisms, similar to LCFAs
